Partnering
Contact
Contact Information
Join Us
EN
CN
About Us
CMS Overview
Leadership
Milestones
Social Responsibility
Innovation
R&D Overview
Pipeline
Business
Business Overview
Cardio-cerebrovascular and Gastroenterology
Dermatology and Medical Aesthetics
Ophthalmology
Southeast Asia Business
News
Company News
Partner News
Investors
Stock Infomation
Financial Highlights
Information Disclosure
Corporate Governance
Investor Communication
Home
About Us
CMS Overview
Leadership
Milestones
Social Responsibility
Innovation
R&D Overview
Pipeline
Business
Business Overview
Cardio-cerebrovascular and Gastroenterology
Dermatology and Medical Aesthetics
Ophthalmology
News
Company News
Partner News
Investors
Investors
Stock Infomation
Financial Highlights
Information Disclosure
Corporate Governance
Partnering
Contact
Contact Information
Join Us
EN
CN
2025-02-05
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2025
2025-01-24
Voluntary and Business Update Announcement Signing a Collaboration Agreement for Class 1 Innovative Drug MG-K10 Humanized Monoclonal Antibody Injection
2025-01-08
Voluntary and Business Update Announcement Signing a License, Collaboration and Distribution Agreement of Improved New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer’s Type
2025-01-02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2024
2024-12-02
Voluntary and Business Update Announcement Gaining Exclusive Commercialization Right of Class 1 Innovative Drug for the Treatment of Gout and Hyperuricemia
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
2024-11-27
Voluntary and Business Update Announcement Approval of Drug Clinical Trials for Innovative Drug Dual Agonist of Glucagon-like Peptide-1 Receptor/Glucagon Receptor CMS-D005
2024-11-05
Voluntary and Business Update Announcement New Drug Application of Ruxolitinib Phosphate Cream for Vitiligo Approved in Hong Kong
2024-11-01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
2024-10-02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
2024-09-24
Voluntary and Business Update Announcement New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China
2024-09-02
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024